15 Fresh Analyst Stock Picks Called to Rise 50% to 100%

Print Email

VOXX International

VOXX International Corp. (NASDAQ: VOXX) was started with an Outperform rating at Oppenheimer on Thursday. The thinly covered small-cap auto components and audio systems player was given a $9 price target, which implied over 70% upside from the prior $5.21 close and the $5.20 close on Friday.

This is the most aggressive of the handful of analysts following VOXX, and its market cap is only $125 million with a 52-week range of $5.05 to $9.85.

And Others

Other more brief analyst summaries this past week with implied upside in the 50% arena, or even 100%, were as follows:

  • AMAG Pharmaceuticals Inc. (NASDAQ: AMAG) was reiterated as Buy with a $70 price target at Jefferies, up over 100% from the prior $28.95 close. The firm says that AMAG is well positioned for upside after resolving temporary disruption from sales integration. Just keep in mind that its stock has been gutted and has lost nearly two-thirds of its value.
  • Amyris Inc. (NASDAQ: AMRS) was started with a Buy rating at Rodman & Renshaw on Tuesday, and it was assigned a price target of $4.00 that implied more than 100% upside from a prior $1.63 close. This $290 million stock closed even lower at $1.51 on Friday.
  • CorMedix Inc. (NASDAQ: CRMD) was started with a Buy rating and a $6.50 price target at Rodman & Renshaw. Friday’s closing price of $2.40 is against a 52-week range of $1.25 to $10.40, and its market cap is a puny $82 million. If you have ever heard of this one, congratulations (maybe).
  • Medgenics Inc. (NYSEMKT: MDGN) was started as Buy with a $12.00 price target (versus a $7.19 a prior close and Friday’s close of $7.15) at Needham. Medgenics has a mere $235 million market cap, and it is a relatively unknown company.
  • Perceptron Inc. (NASDAQ: PRCP) was started as Outperform with an $11 price target (versus a $7.32 close) at FBR Capital Markets. This is a tiny company in automated industrial dimensional inspection and 3D scanning products. It has a mere $70 million market cap and an average daily volume that is so small that some days it trades fewer than 10,000 shares.

ALSO READ: 7 BioHealth Movers Too Big to Ignore

OK, so hopefully you remember that there are big risks in chasing the most aggressive analyst calls. Some of these types of analyst calls do land huge gains, but some of them also crash and burn.

As a final warning, there is even a better than average chance that some of these companies may not even exist a few years from now.